The OBR (Office for Budget Responsibility) anticipates economic output in Britain to expand by 1.8% in 2026 and by 1.5% in ...
Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...
Shares of AstraZeneca dropped more than 7% yesterday after the Chinese publication Yicai Global reported that dozens of ...
Zacks.com on MSN4d
Buy, Sell, or Hold AstraZeneca Stock? Key Tips Ahead of Q3 EarningsKey Takeaways Zacks earnings estimates for AstraZeneca are currently at $4.06 per share. However, the earnings picture ...
Sarepta will discontinue its next generation of exon-skipping drugs for Duchenne muscular dystrophy over safety concerns, in ...
Two current and two former senior AstraZeneca Plc executives in the group’s China unit are under investigation in a probe into alleged breaches of laws around drug importation and data privacy, the ...
The group’s five-point plan provides a window into how drugmakers hoped to influence Trump — who initially backed Medicare negotiations on the campaign trail in 2016 — during the early days of his ...
Lawyers for AstraZeneca, Bristol-Myers Squibb, and Johnson & Johnson argued at a panel hearing in Philadelphia late last week ...
In a frothy market starved for value, these three dividend stocks combine reasonable valuations with the proven ability to ...
The Wall Street Journal on MSN9d
U.S. drugmakers are breaking up with their Chinese supply-chain partnersU.S. drugmakers and biotechs have come to rely on Chinese partners. Now, some of them are looking for alternatives as ...
Greetings and welcome to I US third quarter, 2024 earnings conference call. (Operators Instructions). I would now like to turn the conference over to your host, Jordan Shapiro. Thank you. You may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback